Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 7, 2024CancersOpen Access

Lazertinib versus Platinum-Based Chemotherapy with Epidermal Growth Factor Receptor (EGFR)-Positive Non-Small-Cell Lung Cancer after Failing EGFR-Tyrosine Kinase Inhibitor: A Real-World External Comparator Study

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJun Ho LeeHLHyesung LeeDYDongwon Yoon

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lee et al. (2024) studied this question.

synapsesocial.com/papers/68e65ab4b6db6435875e9566https://doi.org/10.3390/cancers16122169
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC2023 · 657 citations
  2. 2One‐to‐many propensity score matching in cohort studies2012 · 534 citations
  3. 3The Use of External Controls in FDA Regulatory Decision Making2021 · 126 citations
  4. 4Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial2017 · 525 citations
  5. 5Real-time autOmatically updated data warehOuse in healThcare (ROOT): an innovative and automated data collection system2021 · 11 citations